- Home
- OCUP vs RPHM Comparison
OCUP vs RPHM Comparison
Compare OCUP & RPHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUP
- RPHM
- Stock Information
- Founded
- OCUP 2018
- RPHM 2014
- Country
- OCUP United States
- RPHM United States
- Employees
- OCUP N/A
- RPHM N/A
- Industry
- OCUP Biotechnology: Pharmaceutical Preparations
- RPHM Biotechnology: Pharmaceutical Preparations
- Sector
- OCUP Health Care
- RPHM Health Care
- Exchange
- OCUP Nasdaq
- RPHM Nasdaq
- Market Cap
- OCUP 53.1M
- RPHM 47.5M
- IPO Year
- OCUP N/A
- RPHM 2021
- Fundamental
- Price
- OCUP $1.29
- RPHM $1.70
- Analyst Decision
- OCUP Strong Buy
- RPHM Hold
- Analyst Count
- OCUP 3
- RPHM 6
- Target Price
- OCUP $18.67
- RPHM $2.26
- AVG Volume (30 Days)
- OCUP 85.0K
- RPHM 316.0K
- Earning Date
- OCUP 11-11-2024
- RPHM 11-11-2024
- Dividend Yield
- OCUP N/A
- RPHM N/A
- EPS Growth
- OCUP N/A
- RPHM N/A
- EPS
- OCUP N/A
- RPHM N/A
- Revenue
- OCUP $16,449,000.00
- RPHM N/A
- Revenue This Year
- OCUP N/A
- RPHM N/A
- Revenue Next Year
- OCUP $258.69
- RPHM N/A
- P/E Ratio
- OCUP N/A
- RPHM N/A
- Revenue Growth
- OCUP N/A
- RPHM N/A
- 52 Week Low
- OCUP $1.15
- RPHM $0.98
- 52 Week High
- OCUP $3.53
- RPHM $9.21
- Technical
- Relative Strength Index (RSI)
- OCUP 45.88
- RPHM 61.53
- Support Level
- OCUP $1.25
- RPHM $1.61
- Resistance Level
- OCUP $1.33
- RPHM $1.75
- Average True Range (ATR)
- OCUP 0.08
- RPHM 0.12
- MACD
- OCUP 0.01
- RPHM 0.03
- Stochastic Oscillator
- OCUP 16.67
- RPHM 81.25
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
About RPHM Reneo Pharmaceuticals Inc.
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.